
The Purdue Pharma bankruptcy ruling is a developing story that could have far-reaching consequences for families across the country. The company's plan to restructure its debts and create a trust to fund opioid addiction treatment and recovery efforts is a complex issue.
The bankruptcy court's decision could impact the distribution of funds to affected communities, potentially leaving some families without the support they need to recover from opioid addiction. The court's ruling will likely be closely watched by families who have been affected by the opioid crisis.
Purdue Pharma's proposed plan involves creating a trust to distribute funds to communities affected by the opioid crisis. This trust would be funded by a portion of the company's assets, which could total up to $10 billion.
On a similar theme: Finance Purdue Plan of Study
Supreme Court Ruling
The Supreme Court Ruling had a significant impact on the Purdue Pharma bankruptcy case.
The Court's decision allowed Purdue Pharma to restructure its debt under Chapter 11 bankruptcy, rather than facing liquidation.
Take a look at this: Contains Notice of a Proceeding in Bankruptcy Court
Purdue Pharma's bankruptcy plan was approved in September 2021, with the company emerging from bankruptcy in October 2022.
The company's Sackler family owners agreed to pay $6 billion to settle opioid-related claims, but critics argue this is a small fraction of the actual costs.
The bankruptcy plan also created a new entity, Knoa Pharma, to manage the company's opioid products and distribute the settlement funds.
Critics argue that the plan unfairly shields the Sackler family from personal liability.
Intriguing read: Purdue Pharma Family
Financial Consequences
The Sacklers agreed to contribute $6 billion of their personal fortune to help settle the lawsuits, but this contribution came with a condition - a release from all future lawsuit liability.
This deal was made when Purdue Pharma filed for bankruptcy protection in 2019, and it's likely that the Sacklers thought they were getting off relatively easy.
However, some officials involved in the case have spoken out against this deal, arguing that it's far too forgiving.
Financial Lawsuits Dragged On for Years
Financial lawsuits against the Sackler family, who own Purdue Pharma, dragged on for years. These lawsuits were an effort to hold them accountable for the opioid crisis.
Purdue Pharma filed for bankruptcy protection in 2019. This move was likely a desperate attempt to avoid further financial losses.
The Sacklers agreed to contribute $6 billion of their personal fortune to help settle the lawsuits. However, this contribution came with a condition: a release from all future lawsuit liability.
Penalty for Families Affected by Loss
The Sackler family made billions of dollars through the sale of OxyContin, but they're not giving that money back. This is a major concern for those affected by the opioid epidemic.
U.S. Deputy Solicitor General Curtis Gannon commented that the Sacklers were getting off too easy, as they haven't agreed to place their full assets on the table for opioid victims.
Massachusetts AG Maura Healy noted that the Sacklers' attempt to seek protection from liability was problematic, given their massive profits from OxyContin sales.
Sackler Family Involvement
The Sackler family was instrumental in Purdue Pharma's opioid crisis. They made the decisions that led to the company's criminally fraudulent marketing of OxyContin.
A lawsuit filed by Massachusetts Attorney General Maura Healey exposed the Sacklers' involvement in exquisite detail. The lawsuit summarized the actions of the company, including deceiving doctors and patients to get more people on its opioids.
The Sackler family controlled Purdue's misconduct through their seats on the Board of Directors. They held the controlling majority of the Board, giving them full power over both Purdue Pharma Inc. and Purdue Pharma L.P.
The Sacklers directed deceptive sales and marketing practices deep within Purdue, sending hundreds of orders to executives and line employees. They paid themselves and their family billions of dollars from the money Purdue collected selling opioids.
The family's net worth was estimated to be $13 billion in 2016. They extracted approximately $11 billion from the company in the years before the company's 2019 bankruptcy petition.
Here are the Sackler family members who controlled Purdue's misconduct:
- Richard Sackler
- Beverly Sackler
- David Sackler
- Ilene Sackler Lefcourt
- Jonathan Sackler
- Kathe Sackler
- Mortimer Sackler
- Theresa Sackler
Government Response
The government is taking a strong stance against Purdue Pharma's bankruptcy plan. Attorney General Bob Ferguson and 23 other attorneys general from around the country have expressed disappointment with the plan.
They believe it falls short of holding the Sacklers and Purdue accountable for their role in creating the opioid crisis. The states have worked together to force Purdue to turn over millions of pages of evidence and question the Sacklers under oath.
The attorneys general are calling for the plan to be amended to provide for a prompt and orderly wind-down of the company, additional value from the Sacklers to creditors, transparency in the form of robust document disclosures, and protections for nonprofits.
Here are the specific changes they're asking for:
- A prompt and orderly wind-down of the company that does not excessively entangle it with states and other creditors.
- Additional value from the Sacklers to creditors, including the states, to confront the opioid crisis.
- Transparency in the form of robust document disclosures so the public understands the extent of Purdue’s and the Sacklers’ misconduct.
- Protections for nonprofits over naming rights for charitable gifts.
The opioid crisis is a pressing issue, with millions of people suffering from addiction. The attorneys general are committed to working with all parties in the bankruptcy to improve the plan and deliver critically needed assistance to the people of their states.
Frequently Asked Questions
How much did Purdue Pharma pay victims?
Purdue Pharma paid $7.4 billion to settle claims related to the improper marketing of opioids. This massive settlement was approved by all 50 US states and several territories.
Featured Images: pexels.com


